To restore sensitivity to TMZ, we tested pirfenidone (PFN), an anti-fibrotic agent known for inhibiting the TGF-β1 pathway and recently applied in combination with various therapeutic strategies for non-small cell lung cancer, pancreatic cancer, and colorectal cancer [31,32,33,34]. This evidence concerns the gene TGFB1 and pancreatic neoplasm.